ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. The firm invests primarily in companies co-founded with scientists and entrepreneurs. In its life science division, ARCH invests mainly in biopharmaceuticals, bioinformatics, gene therapy, medical devices, and other breakthrough technology. The firm looks mainly for early-stage investment opportunities and focuses on platform technologies. Notable portfolio companies include Alnylam, BIND Biosciences, Elixir Pharmaceuticals, Ensemble Discovery Corp., Fate Therapeutics, Illumina, Trubion Pharmaceuticals, VLST and XenoPort.